Updated KarMMA Data of Ide-Cel in Multiple Myeloma: Larry D. Anderson Jr, MD, PhD

Video

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.

This content is originally from our sister site, OncLive.

OncLive spoke with Larry Anderson, MD, PhD, associate professor, department of internal medicine, division of hematology/oncology, Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, about data from the phase 2 KarMMa trial (NCT03361748).

He discussed outcomes with idecabtagene vicleucel (ide-cel, Abecma) in patients with relapsed/refractory multiple myeloma seen in the trial. Updated results from the trial were presented at the 2021 International Myeloma Workshop and showed that ide-cel yielded a median overall survival (OS) of 24.8 months in heavily pretreated patients with triple-class exposed relapsed/refractory multiple myeloma.

Overall survival was similar for those who had received 3 or more prior lines of therapy, Anderson explains. Additionally, the median OS was more than 20 months for patients with extramedullary and triple-class refractory disease.

The CAR T-cell therapy elicited an overall response rate (ORR) of 73% and resulted in a median progression-free survival (PFS) of 8.6 months, Anderson explains. Notably, in the subset of patients who received the highest dose of CAR T cells, the ORR was even higher, at 81%, with a complete response (CR)rate of 39%. In this subset, the median PFS was 12.2 months, Anderson says.

Notably, responses to ide-cel were durable, with a median duration of response of 10.9 months among all treated patients. The durability increased with depth of response, to 21.5 months of remission for those who achieved a CR and 41% of these patients were still in remission 2 years later, Anderson concludes.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.